Prognostic significance of baseline hypoalbuminemia in lymphoma: a systematic review and meta-analysis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261702Keywords:
Lymphoma, Hypoalbuminemia, Serum albumin, Prognosis, Survival, Meta-analysisAbstract
Lymphomas remain clinically heterogeneous diseases with variable outcomes despite advances in therapy. Reliable prognostic factors are essential to guide treatment planning. Serum albumin, a marker of both nutritional status and systemic inflammation, has been proposed as a simple biomarker of prognosis, but its role across lymphoma subtypes remains unclear. Objectives were to evaluate the association between baseline hypoalbuminemia and survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma (HL). A systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Cochrane Library, and ScienceDirect were searched through June 2025. Cohort studies reporting hazard ratios (HRs) for overall survival (OS) or progression-free survival (PFS) in relation to baseline serum albumin were included. Pooled HRs were calculated using random-effects models. Eight cohort studies with 1,633 patients were included. Hypoalbuminemia was significantly associated with worse OS (HR=2.16; 95% CI: 1.82-2.57; p<0.00001) and poorer PFS (HR=2.49; 95% CI: 1.80-3.45; p<0.00001). These associations remained consistent across lymphoma subtypes, age groups, and treatment contexts, with low to negligible heterogeneity. Notably, patients who achieved albumin recovery during treatment experienced superior outcomes compared with those who remained hypo-albuminemic. The findings underscore albumin’s value as a universally available, inexpensive biomarker that adds prognostic information beyond established indices. Its integration into clinical models may improve risk stratification and support more personalized management. Baseline hypoalbuminemia is a significant adverse prognostic factor in lymphoma. Incorporating serum albumin into routine assessment and considering serial monitoring may enhance prognostic accuracy and patient care.
References
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684-92.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology. 2016;2016(1):366-78.
Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. Longo DL, editor. N Engl J Med. 2021;384(9):842-58.
Yan C, Xie Y, Hua Y, Li S, Fu H, Cheng Z, et al. Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis. Clin Transl Oncol. 2023;26(2):515-23.
Zhang J, Xie Z, Cai S, Qin S, Ruan G, Lu A, et al. Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma. Infect Agent Cancer. 2022;17(1):33.
Hu X, Feng X, Wang H, Miao Y, Lian X, Gao Q, et al. Association between serum albumin levels and survival in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective study. Transl Cancer Res. 2023;12(6):1577-87.
Zhao J, Wu Y. Prognostic value of the controlling nutritional status (CONUT) score in patients with diffuse large B-cell lymphoma: a meta-analysis. World J Surg Oncol. 2025;23(1):28.
Luo C, Li Q, Li X, Wu G, Huang X, Zhang Y, et al. Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation. Ann Transplant. 2021;26: 933365.
Luan C, Wang F, Wei N, Chen B. Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis. Cancer Cell Int. 2020;20(1):455.
Li Y. Prognostic value of the Controlling Nutritional Status score in patients with newly diagnosed multiple myeloma. Am J Transl Res. 2024;16(9):4788-95.
Susanibar‐Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617-29.
Wei X, Zheng J, Zhang Z, Liu Q, Zhan M, Huang W, et al. Consecutive hypoalbuminemia predicts inferior outcome in patients with diffuse large B-cell lymphoma. Front Oncol. 2021;10:610681.
Chen L, Pan L, Liu T. Prognostic value of serum albumin level in patients with diffuse large B-cell lymphoma. Acta Biochim Pol. 2023;70(4):767-76.
Ochi Y, Kazuma Y, Hiramoto N, Ono Y, Yoshioka S, Yonetani N, et al. Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2016;95(1):1-9.
Kaneko H, Shimura K, Yoshida M, Matsumoto Y, Kobayashi T, Uchiyama H, et al. Serum albumin levels strongly predict survival outcome of elderly patients with diffuse large B-cell lymphoma treated with rituximab-combined chemotherapy. Int J Hematol Oncol Stem Cell Res. 2022;16(1):1-8.
Ruiz I, Martelli M, Sehn LH, Vitolo U, Nielsen TG, Sellam G, et al. Baseline total metabolic tumor volume is prognostic for refractoriness to immunochemotherapy in DLBCL: Results from GOYA. Clin Lymphoma Myeloma Leuk. 2022;22(8):e804-14.
Idrobo H, Beltrán BE, Villela L, Torres Viera M, Otero V, Fiad L, et al. Serum albumin is an independent factor predicting survival in patients with peripheral T-cell lymphoma: A multi-institutional study from the Latin American Working Group for Lymphomas (GELL). Blood. 2019;134(1):4047.
Younis MD, Asaad RA, Hussein FH. Baseline serum albumin levels for predicting progression-free survival in patients with non-Hodgkin lymphoma: a single-center prospective study in Syria. J Appl Hematol. 2023;14:287-94.
Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol. 2015;33(4):204-10.
Downloads
Published
How to Cite
Issue
Section
